Which country is Jisandai/Bingtongsha produced?

Epclusa is an oral compound preparation widely used to treat hepatitis C (HCV) around the world. It is developed and produced by the American biopharmaceutical company Gilead Sciences. As a third-generation combination therapy among hepatitis C direct-acting antiviral drugs (DAA), the birth of Epclusa marks the transition of hepatitis C treatment from the era of traditional interferons to a new era that does not require injections, has a higher cure rate, and has lower side effects. The drug was first approved for marketing in the United States in 2016, and was quickly approved in developed countries such as the European Union, Japan, Canada, and Australia, and was gradually promoted to many countries and regions around the world.

Epclusa contains two active ingredients: Sofosbuvir and Velpatasvir. Sofosbuvir, once used as the core ingredient of Sovaldi, is the world's first DAA drug and has established a solid foundation in the field of hepatitis C treatment. Velpatasvir is a pan-genotypic NS5A inhibitor, making Epclusa the first pan-genotypic therapy to cover all six major HCV genotypes. This is why it is called the "third generation".

Although the original research place is the United States, in order to improve global accessibility, low-income or low-middle-income countries such as Laos and Bangladesh imitate and sell cheap versions, with prices far lower than those in the European and American markets. Although these generic drugs are low in price, their ingredients and safety are basically the same.

China has also approved the listing of Gilead III and included it in the medical insurance catalog. Domestic sales are handled by Gilead China. Generally speaking, as a U.S.-origin drug, Jisandai has achieved a "global universal, tiered pricing" strategy through multiple supply routes in the global market, significantly improving the accessibility and fairness of hepatitis C treatment.

Reference: https://www.epclusa.com/